# Aclidinium/Formoterol Fixed Combination Dose Finding Study

> **NCT00626522** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 808 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Aclidinium bromide and formoterol
- **DRUG:** Aclidinium bromide and formoterol placebo

## Key facts

- **NCT ID:** NCT00626522
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 808 (ACTUAL)
- **Last updated:** 2016-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626522, "Aclidinium/Formoterol Fixed Combination Dose Finding Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00626522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*